Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.55 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.48 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.45 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22579036 | 0.98 | TLR8 (0.54) | TLR8GPBAR1CYSLTR1CYSLTR2KDM4E | |
| Phosphine SCHEMBL27716021 | 0.97 | TLR8 (0.52) | TLR8GPBAR1CYSLTR1CYSLTR2KDM4E | |
| SCHEMBL7044155 | 0.88 | TLR8 (0.51) | TLR8GPBAR1CYSLTR1CYSLTR2KDM4E | |
| Hydrochloric Acid SCHEMBL27905861 | 0.87 | TLR8 (0.50) | TLR8GPBAR1CYSLTR1CYSLTR2KDM4E | |
| SCHEMBL28691857 | 0.81 | KDM4E (0.37) | TLR8CYSLTR1CYSLTR2KDM4EALDH1A1 | |
| SCHEMBL30952029 | 0.81 | TLR8 (0.49) | TLR8KDM4ENPC1ALDH1A1MAPT | |
| SCHEMBL3634933 | 0.81 | TLR8 (0.49) | TLR8KDM4ENPC1ALDH1A1MAPT | |
| SCHEMBL716117 | 0.80 | TSHR (0.50) | TLR8KDM4EALDH1A1HPGD | |
| SCHEMBL27364073 | 0.79 | NAAA (0.44) | CYSLTR1CYSLTR2 | |
| SCHEMBL27991341 | 0.79 | TLR8 (0.49) | TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105294578-A | Quinazoline derivative having targeted antitumor activity | GUANGDONG WHOLEWIN TECHNOLOGY CO LTD | 2016-02-03 | — | — | CN | claimed |
| CN-105294578-A | Quinazoline derivative having targeted antitumor activity | GUANGDONG WHOLEWIN TECHNOLOGY CO LTD | 2016-02-03 | — | — | CN | disclosed |
| US-7691866-B2 | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20090317359-A1 | 2,6-DISUBSTITUTED QUINAZOLINES, QUINOXALINES, QUINOLINES AND ISOQUINOLINES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2009-12-24 | — | — | US | disclosed |
| EP-1680122-A1 | 2,6-DISUBSTITUTED QUINAZOLINES, QUINOXALINES, QUINOLINES AND ISOQUINOLINES AS INHIBITORS OF RAF KINASE FOR THE TREATMENT OF CANCER | CHIRON CORPORATION (US) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005037285-A1 | 2,6-DISUBSTITUTED QUINAZOLINES, QUINOXALINES, QUINOLINES AND ISOQUINOLINES AS INHIBITORS OF RAF KINASE FOR TREATMENT OF CANCER | CHIRON CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
| US-20050085482-A1 | 2,6-Disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of RAF kinase | CHIRON CORPORATION (US) | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085482-A1 | 2,6-Disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of RAF kinase | RAF1, BRAF, ARAF | TLR8 4061/4885GPBAR1 4345/4885CYSLTR1 4461/4885 |
| US-20090317359-A1 | 2,6-DISUBSTITUTED QUINAZOLINES, QUINOXALINES, QUINOLINES AND ISOQUINOLINES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | RAF1, BRAF, ARAF | TLR8 4061/4885GPBAR1 4345/4885CYSLTR1 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.